Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
320 studies found for:    biogen | biogen
Show Display Options
Rank Status Study
21 Completed BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis
Conditions: Relapsing-Remitting Multiple Sclerosis;   Multiple Sclerosis
Interventions: Drug: BG00012 (dimethyl fumarate);   Drug: Glatiramer Acetate;   Drug: Interferon beta 1a
22 Completed Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin’s Lymphoma
Conditions: Lymphoma, Non-Hodgkin;   Lymphoma, Low-Grade
Intervention: Drug: ibritumomab tiuxetan (Zevalin®)
23 Completed Investigating if Interferon-Beta Can be Used in Patients With MS After They Have Developed Neutralizing Antibodies
Condition: Relapsing-Remitting Multiple Sclerosis
Interventions: Drug: Interferon-beta-1a;   Drug: methylprednisolone
24 Completed Safety of Avonex Treatment in Multiple Sclerosis Patients With Neutralizing Antibodies to Interferon Beta Therapy
Condition: Multiple Sclerosis
Intervention: Drug: low immunogenic interferon-beta-1a
25 Completed Open-Label Natalizumab Safety Extension Study
Condition: Multiple Sclerosis
Intervention: Drug: Natalizumab
26 Suspended Dose Escalation Study to Determine the Safety of IFN-Beta Gene Transfer in the Treatment of Grade III & Grade IV Gliomas
Conditions: Glioblastoma Multiforme;   Anaplastic Astrocytoma;   Oligoastrocytoma, Mixed;   Gliosarcoma
Intervention: Genetic: Interferon-beta
27 Terminated Evaluation of Safety and Efficacy of Fludarabine, Cyclophosphamide, and Rituximab (FCR) +/- Lumiliximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Condition: Chronic Lymphocytic Leukemia (CLL)
Interventions: Drug: Lumiliximab + FCR;   Drug: FCR
28 Completed BG9928 in Subjects With Hepatic Impairment
Condition: Hepatic Impairment
Intervention: Drug: BG9928
29 Withdrawn BIIB014 Phase 2a Monotherapy
Condition: Parkinson's Disease
Interventions: Drug: active drug (BIIB014) at 10, 30, 100, or 300 mg once daily.;   Drug: placebo
30 Completed Natalizumab in Combination With Glatiramer Acetate (GA) in Patients With Relapsing-Remitting Multiple Sclerosis
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: Natalizumab;   Drug: Placebo
31 Recruiting Study to Evaluate the Pharmacokinetic Profiles of BIIB017 (Peginterferon Beta-1a) and Rebif® (Interferon Beta-1a) in Healthy Volunteers
Condition: Multiple Sclerosis
Interventions: Drug: peginterferon beta-1a;   Drug: Rebif
32 Not yet recruiting Real-world Outcomes on Tecfidera® (BG00012, Dimethyl Fumarate) Post-Tysabri® (BG00002, Natalizumab)
Condition: Relapsing-Remitting Multiple Sclerosis
Interventions: Biological: BG00002 (Natalizumab);   Drug: BG00012 (dimethyl fumarate)
33 Not yet recruiting Observational Study to Establish Patient-Matched Population Norms for the Multiple Sclerosis Cognition Assessment Battery
Condition: Healthy
34 Recruiting Observational Study of Tysabri® in Early Relapsing-Remitting Multiple Sclerosis in Anti-JC Virus (JCV) Antibody Negative Participants
Condition: Relapsing-Remitting Multiple Sclerosis
35 Recruiting Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS)
Condition: Relapsing-Remitting Multiple Sclerosis
Interventions: Drug: dimethyl fumarate;   Drug: Interferon β-1a
36 Not yet recruiting Plegridy™ Observational Program
Condition: Relapsing Forms of Multiple Sclerosis
Intervention: Drug: peginterferon β-1a
37 Recruiting CD INFORM: Investigating Natalizumab Through Further Observational Research and Monitoring
Condition: Crohn's Disease
Intervention: Drug: Natalizumab
38 Not yet recruiting Gastrointestinal Tolerability Study Of Dimethyl Fumarate (DMF) In Participants With Relapsing-Remitting Multiple Sclerosis In Germany
Condition: Relapsing-Remitting Multiple Sclerosis
Intervention: Drug: BG00012
39 Recruiting PK and PD Study of Natalizumab in Pediatric Subjects With RRMS
Condition: Relapsing-Remitting Multiple Sclerosis
Intervention: Biological: Natalizumab
40 Not yet recruiting Natalizumab (BG00002) as an Efficacy Switch in Subjects With Relapsing Multiple Sclerosis (MS) After Failure on Other Therapies
Condition: Relapsing Multiple Sclerosis
Intervention: Drug: Natalizumab

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years